Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care
Appropriations on Alzheimers screening and diagnosis
Discussions regarding H.R. 1319, the American Rescue Plan
Discussions regarding Zero co-payment for biosimilars
Discussions regarding Biogen's Healthy Climate, Healthy Lives initiative
Issues related to the CHANGE Act
Vial size wastage issue Discussions regarding Medicaid 340B drug discount program
Biosimilars shared savings demonstration model in Part B
AMP Cap Discussions regarding H.Con.Res. 11, FY2021 Budget Resolution H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product
Advocate against inclusion of drug pricing as pay-fors in any COVID-19 relief package
Oppose drug pricing proposals that include international procing index (IPI) or similar policies, Medicare drug negotiation, Medicare Part D redesign (including sections in H.R.3, S.2543, H.R.19. S.3129)
HCR - Health Issues MMM - Medicare/Medicaid BUD - Budget/Appropriations PHA - Pharmacy
136 - Centers For Medicare and Medicaid Services (CMS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 136 - Centers For Medicare and Medicaid Services (CMS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 136 - Centers For Medicare and Medicaid Services (CMS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 136 - Centers For Medicare and Medicaid Services (CMS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
BIOGEN
601 PENNSYLVANIA AVENUE, NW #720, WASHINGTON, DC, 20004, US
JONATHAN CAUSEY STEPHANIE A. DYSON MICHELLE MATHY JOHN RAYMOND GIBSON CHUCK SHIH CAROLINE TUCKER MICHELLE MATHY CHRISTINA HOCHUL AMY DEMSKE JONATHAN CAUSEY STEPHANIE A. DYSON JONATHAN CAUSEY MICHELLE MATHY STEPHANIE A. DYSON